Devenport M - Search Results

1

Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues.

Bailey CM, Liu Y, Liu M, Du X, Devenport M, Zheng P, Liu Y, Wang Y. Bailey CM, et al. Among authors: devenport m. J Clin Invest. 2022 May 2;132(9):e150846. doi: 10.1172/JCI150846. J Clin Invest. 2022. PMID: 35239514 Free PMC article.

2

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.

Du X, Liu M, Su J, Zhang P, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y, Zheng P. Du X, et al. Among authors: devenport m. Cell Res. 2018 Apr;28(4):433-447. doi: 10.1038/s41422-018-0012-z. Epub 2018 Feb 20. Cell Res. 2018. PMID: 29463898 Free PMC article.

3

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.

Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, Zheng P, Liu Y. Zhang Y, et al. Among authors: devenport m. Cell Res. 2019 Aug;29(8):609-627. doi: 10.1038/s41422-019-0184-1. Epub 2019 Jul 2. Cell Res. 2019. PMID: 31267017 Free PMC article.

4

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.

Zhang P, Xiong X, Rolfo C, Du X, Zhang Y, Yang H, Russo A, Devenport M, Zhou P, Liu Y, Zheng P. Zhang P, et al. Among authors: devenport m. Cancers (Basel). 2020 Jan 24;12(2):284. doi: 10.3390/cancers12020284. Cancers (Basel). 2020. PMID: 31991588 Free PMC article.

5

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect.

Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S, Li T, Devenport M, Liu Y, Zheng P. Liu M, et al. Among authors: devenport m. Signal Transduct Target Ther. 2022 Jul 15;7(1):224. doi: 10.1038/s41392-022-01030-x. Signal Transduct Target Ther. 2022. PMID: 35835736 Free PMC article. No abstract available.

6

CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.

Wang X, Liu M, Zhang J, Brown NK, Zhang P, Zhang Y, Liu H, Du X, Wu W, Devenport M, Tao W, Mao-Draayer Y, Chen GY, Chen YE, Zheng P, Liu Y. Wang X, et al. Among authors: devenport m. Cell Metab. 2022 Aug 2;34(8):1088-1103.e6. doi: 10.1016/j.cmet.2022.07.005. Cell Metab. 2022. PMID: 35921817 Free PMC article.

7

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.

Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, Zheng P, Liu Y. Du X, et al. Among authors: devenport m. Cell Res. 2018 Apr;28(4):416-432. doi: 10.1038/s41422-018-0011-0. Epub 2018 Feb 22. Cell Res. 2018. PMID: 29472691 Free PMC article.

8

CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS.

Tian RR, Zhang MX, Zhang LT, Zhang P, Ma JP, Liu M, Devenport M, Zheng P, Zhang XL, Lian XD, Ye M, Zheng HY, Pang W, Zhang GH, Zhang LG, Liu Y, Zheng YT. Tian RR, et al. Among authors: devenport m. Antiviral Res. 2018 Sep;157:9-17. doi: 10.1016/j.antiviral.2018.07.004. Epub 2018 Jul 3. Antiviral Res. 2018. PMID: 29983395

9

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.

Song NJ, Allen C, Vilgelm AE, Riesenberg BP, Weller KP, Reynolds K, Chakravarthy KB, Kumar A, Khatiwada A, Sun Z, Ma A, Chang Y, Yusuf M, Li A, Zeng C, Evans JP, Bucci D, Gunasena M, Xu M, Liyanage NPM, Bolyard C, Velegraki M, Liu SL, Ma Q, Devenport M, Liu Y, Zheng P, Malvestutto CD, Chung D, Li Z. Song NJ, et al. Among authors: devenport m. J Hematol Oncol. 2022 Jan 10;15(1):5. doi: 10.1186/s13045-021-01222-y. J Hematol Oncol. 2022. PMID: 35012610 Free PMC article. Clinical Trial.

10

Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.

Welker J, Pulido JD, Catanzaro AT, Malvestutto CD, Li Z, Cohen JB, Whitman ED, Byrne D, Giddings OK, Lake JE, Chua JV, Li E, Chen J, Zhou X, He K, Gates D, Kaur A, Chen J, Chou HY, Devenport M, Touomou R, Kottilil S, Liu Y, Zheng P; SAC-COVID Study Team. Welker J, et al. Among authors: devenport m. Lancet Infect Dis. 2022 May;22(5):611-621. doi: 10.1016/S1473-3099(22)00058-5. Epub 2022 Mar 11. Lancet Infect Dis. 2022. PMID: 35286843 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page